In vitro and in vivo testing methods for respiratory drug delivery

Bibliography

• Rubin BK. Air and soul: the science and application of aerosol therapy. Respir Care 2010;55(7):911-21
   PubMed Web of Science ®Google Scholar
• Takizawa H. Recent development of drug delivery systems for the treatment of asthma and related disorders. Rec Pat Inflamm Allergy Drug Discov 2009;3(3):232-9
   PubMedGoogle Scholar
• Agu RU, Ugwoke MI, Armand M, The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res 2001;2(4):198-209
   PubMed Web of Science ®Google Scholar
• Shoyele SA. Controlling the release of proteins/peptides via the pulmonary route. Methods Mol Biol 2008;437:141-8
   PubMedGoogle Scholar
• El-Sherbiny IM, McGill S, Smyth HD. Swellable microparticles as carriers for sustained pulmonary drug delivery. J Pharm Sci 2010;99(5):2343-56
   PubMed Web of Science ®Google Scholar
• Ari A, Fink JB. Factors affecting bronchodilator delivery in mechanically ventilated adults. Nurs Crit Care 2010;15(4):192-203
   PubMedGoogle Scholar
• Newman SP. Aerosol deposition considerations in inhalation therapy. Chest 1985;88(Suppl):152s-60s
   PubMed Web of Science ®Google Scholar
• Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003;56(6):588-99
   PubMed Web of Science ®Google Scholar
• Li YZ, Sun X, Gong T, Inhalable microparticles as carriers for pulmonary delivery of thymopentin-loaded solid lipid nanoparticles. Pharm Res 2010;27(9):1977-86
   PubMed Web of Science ®Google Scholar
• Malik DK, Baboota S, Ahuja A, Recent advances in protein and peptide drug delivery systems. Curr Drug Deliv 2007;4(2):141-51
   PubMedGoogle Scholar
• Fischer A, Stegemann J, Scheuch G, Novel devices for individualized controlled inhalation can optimize aerosol therapy in efficacy, patient care and power of clinical trials. Eur J Med Res 2009;14(Suppl 4):71-7
   PubMedGoogle Scholar
• Henkin RI. Inhaled insulin-intrapulmonary, intranasal, and other routes of administration: mechanisms of action. Nutrition 2010;26(1):33-9
   PubMed Web of Science ®Google Scholar
• Bao D, Zhao Y. Building membrane emulsification into pulmonary drug delivery and targeting. Pharm Res 2010. [Epub ahead of print]
   Google Scholar
• Newman SP, Clarke SW. Therapeutic aerosols 1–physical and practical considerations. Thorax 1983;38(12):881-6
   PubMed Web of Science ®Google Scholar
• Mitchell JP, Nagel MW, Nichols S, Laser diffractometry as a technique for the rapid assessment of aerosol particle size from inhalers. J Aerosol Med 2006;19(4):409-33
   PubMedGoogle Scholar
• Dolovich M. Measurement of particle size characteristics of metered dose inhaler (MDI) aerosols. J Aerosol Med 1991;4(3):251-63
   PubMedGoogle Scholar
• Mitchell JP, Nagel MW. Cascade impactors for the size characterization of aerosols from medical inhalers: their uses and limitations. J Aerosol Med 2003;16(4):341-77
   PubMedGoogle Scholar
• Heyder J, Gebhart J, Rudolf G, Deposition of particles in the human respiratory tract in the size range 0.005–15. Am J Aerosol Sci 1986;17:811-25
   Web of Science ®Google Scholar
• Dunbar C, Mitchell J. Analysis of cascade impactor mass distributions. J Aerosol Med 2005;18(4):439-51
   PubMedGoogle Scholar
• Stein SW. Aiming for a moving target: challenges with impactor measurements of MDI aerosols. Int J Pharm 2008;355(1-2):53-61
   PubMed Web of Science ®Google Scholar
• Rao N, Kadrichu N, Ament B. Application of a droplet evaporation model to aerodynamic size measurement of drug aerosols generated by a vibrating mesh nebulizer. J Aerosol Med Pulm Drug Deliv 2010. [Epub ahead of print]
   Google Scholar
• Bonam M, Christopher D, Cipolla D, Minimizing variability of cascade impaction measurements in inhalers and nebulizers. AAPS PharmSciTech 2008;9(2):404-13
   PubMed Web of Science ®Google Scholar
• Marple VA, Roberts DL, Romay FJ, Next generation pharmaceutical impactor (a new impactor for pharmaceutical inhaler testing). Part I: design. J Aerosol Med 2003;16:283-99
   PubMedGoogle Scholar
• Andersen AA. New sampler for the collection, sizing, and enumeration of viable airborne particles. J Bacteriol 1958;76:471-84
   PubMed Web of Science ®Google Scholar
• Guo C, Gillespie SR, Kauffman J, Comparison of delivery characteristics from a combination metered-dose inhaler using the Andersen cascade impactor and the next generation pharmaceutical impactor. J Pharm Sci 2008;97(8):3321-34
   PubMed Web of Science ®Google Scholar
• Mitchell JP, Nagel MW, Avvakoumova V, The abbreviated impactor measurement (AIM) concept: part II–Influence of evaporation of a volatile component-evaluation with a ‘droplet-producing’ pressurized metered dose inhaler (pMDI)-based formulation containing ethanol as cosolvent. AAPS PharmSciTech 2009;10(1):252-7
   PubMed Web of Science ®Google Scholar
• Mitchell JP, Nagel MW, Avvakoumova V, The abbreviated impactor measurement (AIM) concept: part 1–Influence of particle bounce and re-entrainment-evaluation with a ‘dry’ pressurized metered dose inhaler (pMDI)-based formulation. AAPS PharmSciTech 2009;10(1):243-51
   PubMed Web of Science ®Google Scholar
• Swithenbank J, Beer JM, Taylor DS. A laser diagnostic technique for the measurement of droplet and particle size distribution. Prog Astronaut Aeronaut 1977;53:421-47
   Google Scholar
• Mitchell JP, Tservistas M. Laser diffractometry and cascade impaction for nebulizer product characterization. Pharmeur Sci Notes 2006;2006(2):49-52
   PubMedGoogle Scholar
• Mitchell JP, Nagel MW. Particle size analysis of aerosols from medicinal inhalers. Kona 2004;22:32-65
   Google Scholar
• Tsagogiorgas C, Krebs J, Pukelsheim M, Semifluorinated alkanes–a new class of excipients suitable for pulmonary drug delivery. Eur J Pharm Biopharm 2010;76(1):75-82
   PubMed Web of Science ®Google Scholar
• Xu Z, Mansour HM, Mulder T, Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate: 1. Albuterol sulfate and disodium cromoglycate. J Pharm Sci 2010;99(8):3398-414
   PubMed Web of Science ®Google Scholar
• Wong W, Fletcher DF, Traini D, Particle aerosolization and break-up in dry powder inhalers 1: evaluation and modelling of venturi effects for agglomerated systems. Pharm Res 2010;27(7):1367-76
   PubMed Web of Science ®Google Scholar
• Ehtezazi T, Saleem I, Shrubb I, The interaction between the oropharyngeal geometry and aerosols via pressurised metered dose inhalers. Pharm Res 2010;27(1):175-86
   PubMed Web of Science ®Google Scholar
• Clark A, Borgstrom L. In vitro testing of pharmaceutical aerosols and predicting lung deposition from in vitro measurements. In: Bisgaard H, O' Callaghan C, Smaldone GC, editors, Drug delivery to the lung. Marcel Dekker, New York, USA; 2002. p. 105-42
   Google Scholar
• Dennis JH, Pieron CA. Quality control and standards in nebulizer performance and use. In: Boe J, O'Driscoll R, Dennis JH, editors, Practical handbook of nebulizer therapy. Martin Dunitz, London, USA; 2004. p. 19-40
   Google Scholar
• Kuhli M, Weiss M, Steckel H. A sampling and dilution system for droplet aerosols from medical nebulisers, developed for use with an optical particle counter. J Aerosol Sci 2009;40:523-33
   Web of Science ®Google Scholar
• Kuhli M, Weiss M, Steckel H. A new approach to characterise pharmaceutical aerosols: measurement of aerosol from a single dose aqueous inhaler with an optical particle counter. Eur J Pharm Sci 2010;39(1-3):45-52
   PubMed Web of Science ®Google Scholar
• Kuhli M, Weiss M, Steckel H. Characterisation of solution-based pressurised metered-dose inhaler aerosols with an optical particle counter. Eur J Pharm Biopharm 2010;75(3):393-8
   PubMed Web of Science ®Google Scholar
• Davies NM, Feddah MR. A novel method for assessing dissolution of aerosol inhaler products. Int J Pharm 2003;255(1-2):175-87
   PubMed Web of Science ®Google Scholar
• Dolovich MB, Jordana M, Newhouse MT. Methodologic considerations in mucociliary clearance and lung epithelial absorption measurements. Eur J Nucl Med 1987;13:S45-52
   PubMedGoogle Scholar
• Salama RO, Traini D, Chan HK, Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation 2: evaluation of in vitro release profiling methodologies for controlled release respiratory aerosols. Eur J Pharm Biopharm 2008;70(1):145-52
   PubMed Web of Science ®Google Scholar
• McConville JT. Development of standardized dissolution test method for inhaled pharmaceutical formulations. Int J Pharm 2009;382(1-2):15-22
   PubMedGoogle Scholar
• Mezzena M, Scalia S, Young PM, Solid lipid budesonide microparticles for controlled release inhalation therapy. AAPS J 2009;11(4):771-8
   PubMed Web of Science ®Google Scholar
• Onoue S, Sato H, Kawabata Y, In vitro and in vivo characterization on amorphous solid dispersion of cyclosporine A for inhalation therapy. J Control Release 2009;138(1):16-23
   PubMed Web of Science ®Google Scholar
• United States Pharmacopeia and National Formulary, United States Pharmacopia Convention, Inc., Rockville, MD, USA, 26th edition., 2003
   Google Scholar
• Beyssac E, Lavigne J. Dissolution study of active pharmaceutical ingredients using the flow through Apparatus USP 4. Dissolution Tech 2005;12(2):23-5
   Google Scholar
• Franz TJ. Percutaneous absorption on the relevance of in vitro data. J Invest Dermatol 1975;64(3):190-5
   PubMed Web of Science ®Google Scholar
• Ungaro F, De Rosa G, Miro A, Cyclodextrins in the production of large porous particles: development of dry powders for the sustained release of insulin to the lungs. Eur J Pharm Sci 2006;28:423-32
   PubMed Web of Science ®Google Scholar
• Kwon MJ, Bae JH, Kim JJ, Long acting porous microparticle for pulmonary protein delivery. Int J Pharm 2007;333:5-9
   PubMed Web of Science ®Google Scholar
• McConville JT, Patel N, Ditchburn N, Use of a novel modified TSI for the evaluation of controlled-release aerosol formulations I. Drug Dev Ind Pharm 2000;26:1191-8
   PubMed Web of Science ®Google Scholar
• Ansoborlo E, Guilmette RA, Hoover MD, Application of in vitro dissolution tests to different uranium compounds and comparison with in vivo data. Radiat Protect Dosim 1998;79:33-7
   Web of Science ®Google Scholar
• Sdraulig S, Franich R, Tinker RA, In vitro dissolution studies of uranium bearing material in simulated lung fluid. J Env Radioactivity 2008;99:527-38
   PubMed Web of Science ®Google Scholar
• Arora P, Sharma S, Garg S. Permeability issues in nasal drug delivery. Drug Discov Today 2002;7:967-75
   PubMed Web of Science ®Google Scholar
• Arora D, Shah KA, Halquist MS, In vitro aqueous fluid-capacity-limited dissolution testing of respirable aerosol drug particles generated from inhaler products. Pharm Res 2010;27(5):786-95
   PubMed Web of Science ®Google Scholar
• Davies NM, Feddah MR. A novel method for assessing dissolution of aerosol inhaler products. Int J Pharm 2003;255(1-2):175-87
   PubMed Web of Science ®Google Scholar
• Grainger CI, Greenwell LL, Martin GP, The permeability of large molecular weight solutes following particle delivery to air-interfaced cells that model the respiratory mucosa. Eur J Pharm Biopharm 2009;71(2):318-24
   PubMed Web of Science ®Google Scholar
• Madlova M, Bosquillon C, Asker D, In-vitro respiratory drug absorption models possess nominal functional P-glycoprotein activity. J Pharm Pharmacol 2009;61(3):293-301
   PubMed Web of Science ®Google Scholar
• Forbes B, Ehrhardt C. Human respiratory epithelial cell culture for drug delivery applications. Eur J Pharm Biopharm 2005;60(2):193-205
   PubMed Web of Science ®Google Scholar
• Castell JV, Donato MT, Gomez-Lechon MJ. Metabolism and bioactivation of toxicants in the lung. The in vitro cellular approach. Exp Toxicol Pathol 2005;57(Suppl 1):189-204
   PubMedGoogle Scholar
• Braun A, Hammerle S, Suda K, Cell cultures as tools in biopharmacy. Eur J Pharm Sci 2000;11(Suppl 2):S51-60
   PubMed Web of Science ®Google Scholar
• Berube K, Prytherch Z, Job C, Human primary bronchial lung cell constructs: the new respiratory models. Toxicology 2010. [Epub ahead of print]
   Google Scholar
• Sporty JL, Horalkova L, Ehrhardt C. In vitro cell culture models for the assessment of pulmonary drug disposition. Expert Opin Drug Metab Toxicol 2008;4(4):333-45
   PubMed Web of Science ®Google Scholar
• Sakagami M. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Deliv Rev 2006;58(9-10):1030-60
   PubMed Web of Science ®Google Scholar
• Fiegel J, Ehrhardt C, Schaefer UF, Large porous particle impingement on lung epithelial cell monolayers–toward improved particle characterization in the lung. Pharm Res 2003;20(5):788-96
   PubMed Web of Science ®Google Scholar
• de Jong PM, van Sterkenburg MA, Kempenaar JA, Serial culturing of human bronchial epithelial cells derived from biopsies. In Vitro Cell Dev Biol Anim 1993;29A(5):379-87
   PubMed Web of Science ®Google Scholar
• Forbes B, Lim S, Martin GP, An in vitro technique for evaluating inhaled nasal delivery systems. STP Pharma 2002;12:75-9
   Web of Science ®Google Scholar
• Cooney D, Kazantseva M, Hickey AJ. Development of a size-dependent aerosol deposition model utilising human airway epithelial cells for evaluating aerosol drug delivery. Altern Lab Anim 2004;32(6):581-90
   PubMed Web of Science ®Google Scholar
• Bur M, Rothen-Rutishauser B, Huwer H, A novel cell compatible impingement system to study in vitro drug absorption from dry powder aerosol formulations. Eur J Pharm Biopharm 2009;72(2):350-7
   PubMed Web of Science ®Google Scholar
• Bur M, Huwer H, Muys L, Drug transport across pulmonary epithelial cell monolayers: effects of particle size, apical liquid volume, and deposition technique. J Aerosol Med Pulm Drug Deliv 2010;23(3):119-27
   PubMed Web of Science ®Google Scholar
• Wiedmann TS, Bhatia R, Wattenberg LW. Drug solubilization in lung surfactant. J Control Release 2000;65(1-2):43-7
   PubMed Web of Science ®Google Scholar
• Sinswat P, Overhoff KA, McConville JT, Nebulization of nanoparticulate amorphous or crystalline tacrolimus–single-dose pharmacokinetics study in mice. Eur J Pharm Biopharm 2008;69(3):105710-66
   Google Scholar
• Pavy-Le Traon A, Saivin S, Soulez-LaRiviere C, Pharmacology in space: pharmacotherapy. Adv Space Biol Med 1997;6:93-105
   PubMedGoogle Scholar
• dos Santos MA, Bosquillona C, Russomano T, Modelling the effects of microgravity on the permeability of air interface respiratory epithelial cell layers. Adv Space Res 2010;46(6):712-18
   Web of Science ®Google Scholar
• Jaafar-Maalej C, Andrieu V, Elaissari A, Fessi H. Assessment methods of inhaled aerosols: technical aspects and applications. Expert Opin Drug Deliv 2009;6(9):941-59
   PubMed Web of Science ®Google Scholar
• Fernandes CA, Vanbever R. Preclinical models for pulmonary drug delivery. Expert Opin Drug Deliv 2009;6(11):1231-45
   PubMed Web of Science ®Google Scholar
• Schanker LS. Drug absorption from the lung. Biochem Pharmacol 1978;27:381-5
   PubMed Web of Science ®Google Scholar
• Chilvers MA, O'Callaghan C. Local mucociliary defence mechanisms. Paediatr Respir Rev 2000;1(1):27-34
   PubMedGoogle Scholar
• Ross HH, Romrell LJ, Kaye GI. Respiratory system, histology – A text and atlas; Williams & Wilkins, Baltimore; 1995. p. 530-57
   Google Scholar
• Saumon G, Soler P, Martet G. Effect of polycations on barrier and transport properties of alveolar epithelium in situ. Am J Physiol 1995;269(2 Pt 1):L185-94
   PubMed Web of Science ®Google Scholar
• Niemeier RW. The isolated perfused lung. Environ Health Perspect 1984;56:35-41
   PubMed Web of Science ®Google Scholar
• Valle MJ, Gonzalez LF, Sanchez NA. Pulmonary versus systemic delivery of levofloxacin. The isolated lung of the rat as experimental approach for assessing pulmonary inhalation. Pulm Pharmacol Ther 2008;21(2):298-303
   PubMed Web of Science ®Google Scholar
• Saumon G, Soler P, Martet G. Effect of polycations on barrier and transport properties of alveolar epithelium in situ. Am J Physiol 1995;269(2 Pt 1):L185-94
   PubMed Web of Science ®Google Scholar
• Eljamal M, Nagarajan S, Patton JS. In situ and in vivo methods for pulmonary delivery. Pharm Biotechnol 1996;8:361-74
   PubMedGoogle Scholar
• Newman SP, Chan HK. In vitro/in vivo comparisons in pulmonary drug delivery. J Aerosol Med Pulm Drug Deliv 2008;21(1):77-84
   PubMed Web of Science ®Google Scholar
• Newman SP, Wilding IR, Hirst PH. Human lung deposition data: the bridge between in vitro and clinical evaluations for inhaled drug products? Int J Pharm 2000;208(1-2):49-60
   PubMed Web of Science ®Google Scholar
• Bur M, Henning A, Hein S, Inhalative nanomedicine–opportunities and challenges. Inhal Toxicol 2009;21(Suppl 1):137-43
   PubMedGoogle Scholar
• Jaafar-Maalej C, Andrieu V, Elaissari A, Assessment methods of inhaled aerosols: technical aspects and applications. Expert Opin Drug Deliv 2009;6(9):941-59
   PubMed Web of Science ®Google Scholar
• Kim CS. Methods of calculating lung delivery and deposition of aerosol particles. Respir Care 2000;45(6):695-711
   PubMedGoogle Scholar
• Cryan SA, Sivadas N, Garcia-Contreras L. In vivo animal models for drug delivery across the lung mucosal barrier. Adv Drug Deliv Rev 2007;59(11):1133-51
   PubMed Web of Science ®Google Scholar
• Fleming JS, Hashish AH, Conway JH, Assessment of deposition of inhaled aerosol in the respiratory tract of man using three-dimensional multimodality imaging and mathematical modeling. J Aerosol Med 1996;9(3):317-27
   PubMedGoogle Scholar
• Schroeter J, Fleming J, Hwang D, A computer model of lung morphology to analyze SPECT images. Comput Med Imaging Graph 2002;26(4):237-46
   PubMed Web of Science ®Google Scholar
• Hindle M, Chrystyn H. Determination of the relative bioavailability of salbutamol to the lung following inhalation. Br J Clin Pharmacol 1992;34(4):311-15
   PubMed Web of Science ®Google Scholar
• Lee SL, Adams WP, Li BV, In vitro considerations to support bioequivalence of locally acting drugs in dry powder inhalers for lung diseases. AAPS J 2009;11(3):414-23
   PubMed Web of Science ®Google Scholar
• Tomlinson HS, Corlett SA, Chrystyn H. Effect of dose on the relative lung bioavailability of salbutamol. J Aerosol Med 1995;8:P193
   Google Scholar
• Silkstone VL, Corlett SA, Chrystyn H. Relative lung and total systemic bioavailability following inhalation from a metered dose inhaler compared with a metered dose inhaler attached to a large volume plastic spacer and a jet nebulizer. Eur J Clin Pharmacol 2002;57(11):781-6
   PubMed Web of Science ®Google Scholar
• Chrystyn H, Allen MB, Corlett SA. Simultaneous measurement of pharmacodynamic and pharmacokinetic parameters which can be used to evaluate the equivalence of inhaled salbutamol. Am Rev Respir Crit Care Med 1998;157:A636
   Google Scholar
• Lipworth B. Pharmacokinectics of inhaled drugs. Br J Clin Pharmacol 1996;42(6):697-705
   PubMed Web of Science ®Google Scholar
• Finlay WH, Martin AR. Recent advances in predictive understanding of respiratory tract deposition. J Aerosol Med Pulm Drug Deliv 2008;21(2):189-206
   PubMed Web of Science ®Google Scholar
• de Matas M, Shao Q, Silkstone VL, Evaluation of an in vitro in vivo correlation for nebulizer delivery using artificial neural networks. J Pharm Sci 2007;96(12):3293-303
   PubMed Web of Science ®Google Scholar
• Kunka R, Andrews S, Pimazzoni M, From hydrofluoroalkane pressurized metered dose inhalers (pMDIs) and comparability with chlorofluorocarbon pMDIs. Respir Med 2000;94(Suppl B):S10-16
   Google Scholar
• Silkstone VL, Dennis JH, Pieron CA, An investigation of in vitro/in vivo correlations for salbutamol nebulized by eight systems. J Aerosol Med 2002;15(3):251-9
   PubMedGoogle Scholar
• Srichana T, Suedee R, Muanpanarai D, The study of in vitro-in vivo correlation: pharmacokinetics and pharmacodynamics of salbutamol dry powder inhalers. J Pharm Sci 2005;94(1):220-30
   PubMed Web of Science ®Google Scholar
• de Matas M, Shao Q, Richardson CH, Evaluation of in vitro in vivo correlations for dry powder inhaler delivery using artificial neural networks. Eur J Pharm Sci 2008;33(1):80-90
   PubMed Web of Science ®Google Scholar
• Warheit DB, Sayes CM, Reed KL. Nanoscale and fine zinc oxideparticles: can in vitro assays accurately forecast lung hazardsfollowing inhalation exposures? Environ Sci Technol 2009;43(20):7939-45
   PubMed Web of Science ®Google Scholar